Hormonal
GLP-1 receptor agonists reduce the risk of heart failure hospitalization, with the most significant relative risk reduction observed in patients with heart failure with preserved ejection fraction (HFpEF) who have obesity.
If you have heart failure with preserved ejection fraction (HFpEF) and are overweight or obese, GLP-1 medications like semaglutide or efpeglenatide may significantly reduce your risk of being hospitalized for heart failure. These drugs work by improving blood sugar, reducing weight, and lowering inflammation. While not yet a standard treatment for all heart failure, they are a promising option, especially for those with obesity.
In sum, current evidence positions GLP-1 RAs as a potential cardioprotective strategy in HF, with HF with preserved ejection fraction emerging as the relevant phenotype for the drug class, especially when occurring in people with obesity with and without diabetes.
Why this rating
Based on large CVOTs and meta-analyses, though dedicated HF-specific trials are still needed.
Source
The potential of glucagon-like peptide-1 receptor agonists in heart failure
Frederik Flindt Kreiner et al. · Frontiers in Physiology · 2022
DOI 10.3389/fphys.2022.983961
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →